NCT00779467

Brief Summary

The purpose of this study is to see which dose of epidural neostigmine is the best additive to use with the numbing medication used in an epidural during labor.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Oct 2008

Longer than P75 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2008

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

October 22, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 24, 2008

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2013

Completed
3.4 years until next milestone

Results Posted

Study results publicly available

April 10, 2017

Completed
Last Updated

September 11, 2018

Status Verified

August 1, 2018

Enrollment Period

5.1 years

First QC Date

October 22, 2008

Results QC Date

October 27, 2016

Last Update Submit

August 13, 2018

Conditions

Keywords

non narcoticepidurallabor painNon narcotic treatment of labor pain

Outcome Measures

Primary Outcomes (1)

  • Amount of Drug Consumed Per Hour in Each Group(Arm)

    Median hourly total bupivacaine consumption. Drug amount consumed per hour of each group (arm)

    until delivery

Secondary Outcomes (7)

  • Nausea

    until delivery

  • Sedation

    until delivery

  • Shivering

    until delivery

  • Pruritus

    until delivery

  • Bromage Score

    until delivery

  • +2 more secondary outcomes

Study Arms (4)

Bupivacaine with Neostimgine 8 mcg/ml

EXPERIMENTAL

STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML

Drug: NeostigmineDrug: Bupivacaine

Bupivacaine and Neostigmine 4 mcg/ml

EXPERIMENTAL

STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML

Drug: NeostigmineDrug: Bupivacaine

Bupivacaine with Neostigmine 2 mcg/ml

EXPERIMENTAL

STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML

Drug: NeostigmineDrug: Bupivacaine

BUPIVACAINE WITH FENTANYL 2 MCG/ML

ACTIVE COMPARATOR

Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION

Drug: BupivacaineDrug: fentanyl

Interventions

utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.

Bupivacaine and Neostigmine 4 mcg/mlBupivacaine with Neostigmine 2 mcg/mlBupivacaine with Neostimgine 8 mcg/ml
BUPIVACAINE WITH FENTANYL 2 MCG/MLBupivacaine and Neostigmine 4 mcg/mlBupivacaine with Neostigmine 2 mcg/mlBupivacaine with Neostimgine 8 mcg/ml

fentanyl 2 mcg/ml

BUPIVACAINE WITH FENTANYL 2 MCG/ML

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy pregnancy
  • Term pregnancy ( \> 37 weeks)
  • Primiparous or multiparous
  • Induction or spontaneous labor greater or = 18 years of age
  • Cervical exam on entry \</=5 cm

You may not qualify if:

  • Weight \> 115 kg
  • Non-English speaking
  • IV analgesics within 60 minutes prior to epidural being administered
  • Allergy to local anesthetics or neostigmine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Forsyth Medical Center

Winston-Salem, North Carolina, 27103, United States

Location

MeSH Terms

Conditions

Labor Pain

Interventions

NeostigmineBupivacaineFentanyl

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Phenylammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic ChemicalsOnium CompoundsAnilidesAmidesAniline CompoundsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Results Point of Contact

Title
Peter H. Pan, MD, MSEE
Organization
Wake Forest School of Medicine

Study Officials

  • Peter H Pan, MD

    Wake Forest University Health Sciences OB Anesthesia

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 22, 2008

First Posted

October 24, 2008

Study Start

October 1, 2008

Primary Completion

November 1, 2013

Study Completion

November 1, 2013

Last Updated

September 11, 2018

Results First Posted

April 10, 2017

Record last verified: 2018-08

Locations